175 related articles for article (PubMed ID: 11254555)
1. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model.
Stiles BG; Garza AR; Ulrich RG; Boles JW
Infect Immun; 2001 Apr; 69(4):2031-6. PubMed ID: 11254555
[TBL] [Abstract][Full Text] [Related]
2. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.
Lowell GH; Kaminski RW; Grate S; Hunt RE; Charney C; Zimmer S; Colleton C
Infect Immun; 1996 May; 64(5):1706-13. PubMed ID: 8613381
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.
Lowell GH; Colleton C; Frost D; Kaminski RW; Hughes M; Hatch J; Hooper C; Estep J; Pitt L; Topper M; Hunt RE; Baker W; Baze WB
Infect Immun; 1996 Nov; 64(11):4686-93. PubMed ID: 8890226
[TBL] [Abstract][Full Text] [Related]
4. Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.
Fernandez S; Cisney ED; Hall SI; Ulrich RG
Clin Vaccine Immunol; 2011 Apr; 18(4):667-75. PubMed ID: 21325486
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization of mutant toxic shock syndrome toxin 1 elicits systemic and mucosal immune response against Staphylococcus aureus infection.
Narita K; Hu DL; Tsuji T; Nakane A
FEMS Immunol Med Microbiol; 2008 Apr; 52(3):389-96. PubMed ID: 18312579
[TBL] [Abstract][Full Text] [Related]
6. Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon.
Lee JS; Dyas BK; Nystrom SS; Lind CM; Smith JF; Ulrich RG
J Infect Dis; 2002 Apr; 185(8):1192-6. PubMed ID: 11930333
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection.
Hu DL; Omoe K; Sasaki S; Sashinami H; Sakuraba H; Yokomizo Y; Shinagawa K; Nakane A
J Infect Dis; 2003 Sep; 188(5):743-52. PubMed ID: 12934191
[TBL] [Abstract][Full Text] [Related]
8. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.
Glenn GM; Scharton-Kersten T; Vassell R; Mallett CP; Hale TL; Alving CR
J Immunol; 1998 Oct; 161(7):3211-4. PubMed ID: 9759833
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens.
Bavari S; Ulrich RG; LeClaire RD
J Infect Dis; 1999 Oct; 180(4):1365-9. PubMed ID: 10479174
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
11. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
[TBL] [Abstract][Full Text] [Related]
12. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity.
Nochi T; Yuki Y; Katakai Y; Shibata H; Tokuhara D; Mejima M; Kurokawa S; Takahashi Y; Nakanishi U; Ono F; Mimuro H; Sasakawa C; Takaiwa F; Terao K; Kiyono H
J Immunol; 2009 Nov; 183(10):6538-44. PubMed ID: 19880451
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
Morefield GL; Hawkins LD; Ishizaka ST; Kissner TL; Ulrich RG
Clin Vaccine Immunol; 2007 Nov; 14(11):1499-504. PubMed ID: 17715328
[TBL] [Abstract][Full Text] [Related]
14. Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model.
Inskeep TK; Stahl C; Odle J; Oakes J; Hudson L; Bost KL; Piller KJ
Clin Vaccine Immunol; 2010 Aug; 17(8):1163-9. PubMed ID: 20554806
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant.
Kende M; Del Giudice G; Rivera N; Hewetson J
Vaccine; 2006 Mar; 24(12):2213-21. PubMed ID: 16325310
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of the histidine-to-tyrosine staphylococcal enterotoxin B mutant protein in C3H/HeJ mice.
Savransky V; Pinelis D; Korolev S; Ionin B; Fegeding K
Toxicon; 2004 Mar; 43(4):433-8. PubMed ID: 15051407
[TBL] [Abstract][Full Text] [Related]
17. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72.
Kende M; Tan X; Wlazlowski C; Williams R; Lindsey C; Del Giudice G
Vaccine; 2007 Apr; 25(16):3219-27. PubMed ID: 17343960
[TBL] [Abstract][Full Text] [Related]
19. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection.
Cui JC; Hu DL; Lin YC; Qian AD; Nakane A
FEMS Immunol Med Microbiol; 2005 Jul; 45(1):45-51. PubMed ID: 15985222
[TBL] [Abstract][Full Text] [Related]
20. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
Strindelius L; Filler M; Sjöholm I
Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
